Drugs for weight loss are top of mind but out of reach for many despite wide-ranging benefits.
Agents like semaglutide show promise for treatment of substance use disorders.pressed the chief executive officer of Novo Nordisk to lower prices of popular weight-loss drugs such as semaglutide – marketed in the United States as Wegovy and Ozempic. The September 24hearing interested many Americans currently struggling with the high cost of obtaining these drugs to aid their own weight loss journeys.
Significant price disparities for prescription drugs are often the norm rather than the exception in the United States. In the Senate hearing in late September noted above, the cost of Ozempic was cited asin the United States than in Germany . Current US pricing of Wegovy at $1,349 far surpasses the cost of the same drug in Denmark and makes acquiring this
Of course, the popularity and efficacy of GLP-1 agonists for weight loss must be balanced against risk of known side effects. Gastrointestinal distress, including nausea, vomiting, and acute pancreatitis is more common with use of GLP-1 agonists. In December 2023, the US Food and Drug Administration’sideation with GLP-1 agonists, although no corresponding rise in suicidal behavior, attempts, or completed suicides was noted.
GLP-1 agonists represent a turning point in the pharmacological treatment of obesity. Their potential benefit and reach may well extend beyond obesity. However, popularity and desirability should not eclipse the need for due diligence and further investigation. Clinical equipoise must dictate the future role of GLP-1 agonists in the treatment of other medical andconditions.
is the Medical Director of Emergency Psychiatric Services and Visiting Associate Professor of Psychiatry at the University of Colorado Hospital.It’s increasingly common for someone to be diagnosed with a condition such as ADHD or autism as an adult. A diagnosis often brings relief, but it can also come with as many questions as answers.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Considering Eating Disorder Potential When Prescribing Weight Loss Drugs to TeensPhysicians fear use of weight loss drugs in teens will increase or exacerbate eating disorder cases, adding complexity to treatment.
続きを読む »
Ozempic, Wegovy maker Novo Nordisk faces hearing over high cost of weight loss drugsBlockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard Jørgensen who helmed it all, and presses him on the high price, drug shortages, and long-term effects.
続きを読む »
Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugsIs Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO is scheduled to testify Tuesday on Capitol Hill.
続きを読む »
Body AcceptanceEating disorders and dieting in the age of weight loss drugs.
続きを読む »
What we know in 2024 about drug overdoses among adolescents.Adolescents are often victimized and even die from counterfeit drugs that are really fentanyl.
続きを読む »
Better together: Gut microbiome communities found to have enhanced resilience to drugsMany human medications can directly inhibit the growth and alter the function of the bacteria that constitute our gut microbiome. EMBL Heidelberg researchers have now discovered that this effect is reduced when bacteria form communities.
続きを読む »